GOLD SPONSORS
SILVER SPONSORS
EXHIBITORS
SPONSOR


HPS was founded in 2015 and has a seasoned management team with over 75 years of HIFU experience. HPS is the first, largest, and most experienced HIFU team in the U.S. and has been involved in over 5,000 HIFU procedures, and the first company to reach the 1,500 treatment threshold inside the US. The HPS network currently has over 700 physicians across the U.S., and our physician proctors have experience with over 4,000 HIFU procedures. The company is headquartered in Charlotte, NC and has established partnerships with physicians and urology practices throughout the country. For additional information, visit the website.


EDAP TMS is actively operating worldwide via an extensive network of subsidiaries, corporate offices, and distribution partners. The company is currently marketing two ranges of urology products dedicated to localized prostate cancer and urinary stones. EDAP TMS is also developing its innovative technologies to expand applications beyond urology.
With its complete range of Robotic devices using HIFU (High Intensity Focused Ultrasound), EDAP TMS is the most innovative company in minimally invasive treatment for localized prostate cancer. By combining the latest technologies in imaging and treatment modalities, EDAP TMS introduced the Focal One® as the answer to all requirements for ideal focal therapy of prostate cancer and as a complement to its existing Ablatherm® HIFU device.
Also pioneer and key player in the field of Extracorporeal ShockWave Lithotripsy (ESWL) for urinary stones, EDAP TMS introduced its latest modular lithotripter Sonolith® i-move utilizing the latest generation of shock wave source together with an exclusive unconstrained proprietary ultrasound system (“Visio-Track”) developed by EDAP TMS.






Based in Toronto, Canada, Focal Healthcare has developed an MRI/TRUS fusion targeted guidance system for prostate biopsy and therapy. By combining information from multiparametric MRI with a semi-robotic arm and user-friendly interface, the Fusion Bx 2.0™ gives urologists the ability to perform targeted transrectal and transperineal prostate biopsies.

BK Medical’s bkFusion is a fully integrated prostate fusion biopsy solution with simultaneous display of MRI and real-time ultrasound images on one monitor. bkFusion combines unmatched image quality with a familiar and easy workflow to help make prostate biopsy procedures in either the free-hand transrectal or the transperineal approach as efficient as possible. The urologist maintains control of the entire procedure and can freely adjust ultrasound gain and depth or choose to scan in different planes (transverse, sagittal and end-fire) to better target areas of concern, without the need to resweep or recalibrate during procedures.


As part of our curated services offering, we provide a dedicated patient care team consisting of patient and caregiver ambassadors, insurance reimbursement specialist, and nursing support.




SmartBlate is convenient given that it offers a fast and safe in-office procedure performed in less than ninety (90) minutes, optimal via precise destruction of localized cancer tissue while sparing healthy tissue, and practical as no general anesthesia is required, with minimal post-procedure care.

Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO® is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient’s natural functional abilities. We believe TULSA-PRO® is demonstrating to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer, and the transition zone in large volume benign prostatic hyperplasia (BPH). TULSA-PRO® is CE marked and received 510(k) clearance from the U.S. Food and Drug Administration in August 2019.

Navigo is the only real-time 3D Fusion navigation system with automatic patient movement compensation and automatic needle detection capabilities, providing unmatched accuracy during biopsy and treatment procedures. Navigo is ultrasound agnostic and has guided thousands of TRUS and TP procedures in office and OR settings. Navigo is widely used by Academic centers and private practices taking advantage of its superior performance and competitive pricing.
SmartBx is the first and only solution for in specimen navigation. SmartBx is a unique biopsy management solution that will safeguard the biopsy specimen and enable accurate cancer localization. Proven over large-scale trials, SmartBx showed significant increase in detection rate! While lowering pathology costs by as much as 50%. SmartBx will enhance any Fusion navigation system and is the only available solution that can truly enable Active Surveillance & Focal Therapy.

We are committed to delivering the most accurate tests for determining the true nature of prostate and bladder cancers, enabling each patient to have a treatment plan based on the unique biology of their tumor.
Accreditation | |
![]() Duke University Health System Department of Clinical Education & Professional Development designates this live activity for a maximum of 20.25 Credits. Read more » |
Compliance | |
![]() The 12th International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer is compliant with the provisions of the MedTech Europe Code of Ethical Business Practice and Mecomed Code of Business Practice. Read more » |
Important Warning Please be aware of fraudulent websites or emails being presented as coming from the official congress organizer or official housing office. Read more IMPORTANT WARNING
|
Add to your Calendar |